Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-Liver: Immunotherapy Combinations in Advanced Liver Cancers
NCT04524871Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2020
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of tiragolumab, tocilizumab, amezalpat, tobemstomig, muzastotug in hepatocellular carcinoma (HCC), sponsored by Roche. Started Nov 2020; status: active, not recruiting.
02
Drugs
tiragolumabtocilizumabamezalpattobemstomigmuzastotug
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04524871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524871.